diff --git a/app/components/Layout/Header.jsx b/app/components/Layout/Header.jsx index 0e1aa8a..6ad9460 100644 --- a/app/components/Layout/Header.jsx +++ b/app/components/Layout/Header.jsx @@ -370,14 +370,32 @@ const Header = () => { -
+ Empowering you with precise, tailored approaches to diagnostics and care — + addressing the unique needs of each clinical area to improve patient outcomes. +
+ + {/* Cards */} ++ Advancing diagnostics and treatments for rare genetic conditions. +
++ Revolutionizing cancer care with targeted therapies and early detection. +
++ At Operify Health, we believe every patient deserves answers that are not only + accurate — but actionable. By harnessing the power of Next Generation Sequencing + (NGS), we transform patient samples into rich genomic insights that enable + clinicians and oncologists to make informed, personalized decisions. From rare + genetic disorders to complex oncological cases, our solutions help uncover what + traditional diagnostics often miss. +
++ Our strength lies in our multidisciplinary team of researchers, bioinformaticians, + and data scientists who use custom-built algorithms and cutting-edge analytics to + interpret genetic data with unmatched depth. Backed by curated scientific evidence + and real-world clinical findings, we deliver recommendations that are current, + relevant, and patient-focused. +
++ With every genome we decode, we move closer to truly personalized medicine — + bridging data and care, science and life. +
+{f.desc}
++ About 5-10% of all cancers are linked to inherited genetic mutations, often going + undetected until late stages or after multiple family members are affected. +
++ The Operify Hereditary Cancer Panel screens key high- and moderate-risk genes associated + with hereditary cancer syndromes like HBOC, Lynch Syndrome (LS), Li Fraumeni Syndrome (LFS), + Familial Adenomatous Polyposis (FAP), Cowden Syndrome (CS), Peutz-Jeghers Syndrome (PJS), + Neurofibromatosis (NF) etc. +
++ Early identification of germline mutations enables proactive clinical decisions, including + risk-reducing strategies, targeted surveillance, and family cascade testing. +
++ Studies show that genetic testing in hereditary cancer cases improves outcomes and informs + care for both patients and at-risk relatives. +
+| Feature | +Description | +
|---|---|
| {feature.title} | +{feature.desc} | +
+ Cancer is not a single disease—it's a highly complex and dynamic group of disorders, + often driven by a multitude of genomic alterations. Despite advancements in treatment, + many patients still face uncertainty due to incomplete or delayed molecular diagnoses. +
++ At Operify Health, we recognize that behind every tumor is a unique genetic story waiting + to be told. Our precision oncology solutions utilize high-throughput Next Generation + Sequencing (NGS) to analyze both somatic and germline mutations—providing clinicians + with actionable insights that inform targeted therapies, immunotherapy decisions, and + hereditary cancer risk assessments. +
++ This genomic-driven approach is especially critical in advanced and treatment-resistant + cancers, where conventional methods often fall short. Studies have shown that integrating + broad-panel NGS into cancer care can impact clinical decision-making in up to 30% of cases, + leading to more personalized and effective treatment strategies. +
++ By combining cutting-edge sequencing, advanced bioinformatics, and curated clinical evidence, + Operify Health empowers oncologists to move from uncertainty to precision—ensuring every cancer + patient's care is as individualized as their diagnosis. +
++ Whole Exome Sequencing (WES) targets the protein-coding regions of the genome, where most + disease-causing mutations are found. +
++ With over 7,000 rare diseases identified—80% of which have a genetic basis—WES offers a + powerful approach to uncover their causes. +
++ Traditional diagnostic methods can be slow, costly, and inconclusive; WES streamlines the + process by delivering broad genetic insights in a single test. +
++ Operify Exome enhances WES by combining comprehensive coverage with advanced interpretation, + improving diagnostic yield and patient outcomes. +
+| Feature | +Description | +
|---|---|
| {feature.title} | +{feature.desc} | +
+ The Operify ExomeMito Panel offers a unified solution by integrating whole exome sequencing + with complete mitochondrial genome analysis—addressing both nuclear and mitochondrial causes + of disease. +
++ This combined approach is especially valuable in diagnosing complex, multisystemic, and rare + disorders, where variants may exist across both genomes. +
++ Mitochondrial disorders, though individually rare, are clinically significant, affecting + approximately 1 in 5,000 individuals and often missed in standard testing. +
++ Studies show that adding mitochondrial sequencing to exome testing increases diagnostic + yield by up to 20%, offering greater clarity and clinical confidence. (PMID: 30369941) +
++ While screening for rare genetic disorders, it's essential not to overlook the rarest among + them-mitochondrial disorders, which occur in approximately 1 in 5,000 individuals. Although + individually rare, their cumulative impact is significant in the context of rare disease + diagnostics. Multiple studies have demonstrated a substantial increase in diagnostic yield—up + to 20%—when mitochondrial genome sequencing is performed alongside whole exome sequencing. + Reference: PMID: 30369941 +
+| Genome | +Coverage | +
|---|---|
| {item.genome} | +{item.coverage} | +
| Feature | +Description | +
|---|---|
| {feature.title} | +{feature.desc} | +
+ There are over 7,000 identified rare diseases, many of which begin in childhood—and + nearly 80% have a genetic cause. Yet, the average time to diagnose a rare disorder is + still 4.8 years, with some cases taking up to 20 years. +
++ At Operify Health, we leverage advanced Next Generation Sequencing (NGS) and proprietary + bioinformatics to deliver rapid, reliable insights—helping reduce the diagnostic journey + from years to days. +
+21 Days
+Blood/Saliva/Cheek Swab/Genomic DNA/Dry Blood Spot
+{sol.desc}
++ Whole Exome Sequencing (WES) is recommended for individuals with unexplained genetic + disorders, complex or atypical clinical presentations, or when prior genetic tests + have been inconclusive. +
++ It is especially valuable in diagnosing rare inherited diseases, uncovering the cause + of developmental delays, intellectual disabilities, or early-onset neurological + conditions, and providing insights for personalized treatment planning. +
++ WES can help identify genetic causes in a wide range of rare disorders. +
+Please provide SVG content or URL
Please provide SVG content or URL